3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Colorectal Neoplasms
58
Colonic Neoplasms
24
Rectal Neoplasms
22
Neoplasms
19
Pancreatic Neoplasms
18
Neoplasm Metastasis
17
Esophageal Neoplasms
9
Stomach Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
6
Small Cell Lung Carcinoma
5
Lung Neoplasms
5
Glioma
5
Glioblastoma
5
Brain Neoplasms
5
Neuroblastoma
4
Gliosarcoma
4
Esophageal Squamous Cell Carcinoma
4
Carcinoma, Renal Cell
4
Melanoma
3
Intestinal Neoplasms
3
Gastrointestinal Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Sarcoma, Ewing
2
Recurrence
2
Rectal Diseases
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Interventions
etoposide phosphate
1
Transplantation, Homologous
1
Transplantation, Autologous
1
Therapeutics
1
Temozolomide
1
Radiotherapy
1
RRx-001
1
Patient Discharge
1
Microarray Analysis
1
Irinotecan
1
Immunohistochemistry
1
Ifosfamide
1
Dexamethasone
1
Dasatinib
1
Carboplatin
1
Calcium Dobesilate
1
Bone Transplantation
1
Blotting, Western
1
3-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Spinal Cord Neoplasms
×
Irinotecan
×
Clear all
NCT04525014
2024-10-31
PIRATE
EpicentRx, Inc.
Phase 1
Terminated
2 enrolled